2nd unmet challenges in high risk scientific board
Post on 16-Oct-2021
3 Views
Preview:
TRANSCRIPT
2nd editionUnmet challenges in high risk hematological malignancies: from benchside to clinical practiceTurin, September 13-14, 2021 Starhotels Majestic
Scientific board: Marco Ladetto (Alessandria)Umberto Vitolo (Candiolo-TO)
1
AUSPICES FACULTY
UNIVERSITÀ DEL PIEMONTE ORIENTALE
ISTITUTO DI CANDIOLO - FONDAZIONE DEL PIEMONTE PER L’ONCOLOGIA - IRCCS
AZIENDA OSPEDALIERA DI ALESSANDRIA SANTI ANTONIO E BIAGIO E CESARE ARRIGO
UNIVERSITÀ DI TORINO
AZIENDA OSPEDALIERO-UNIVERSITARIACittà della Salute e della Scienza di Torino - Presidio Ospedaliero Le Molinette
FIL - Fondazione Italiana Linfomi
GITMO - Gruppo Italiano per il Trapianto di Midollo Osseo, cellule staminali emopoietiche e terapia cellulare
SIE - Società Italiana di Ematologia
SIES - Società Italiana di Ematologia Sperimentale
RETE ONCOLOGICA DEL PIEMONTE E DELLA VALLE D’AOSTA
Emanuele AngelucciStephen M. AnsellHervé Avet LoiseauMonica BalzarottiRenato BassanMario BoccadoroAlan K. BurnettAngelo Michele CarellaAnnalisa ChiappellaDaniela CilloniAntonio CuneoBrunangelo FaliniSimone FerreroRobin FoàNathan H. Fowler Gianluca GaidanoPaolo GhiaJohn GribbenPaola GuglielmelliOlivier HermineWolfgang HiddemannPeter HillmenMartin Hutchings Nicolaus Kroeger Marco Ladetto
Genoa, ItalyRochester, USAToulouse, FranceRozzano (MI), ItalyMestre (VE), ItalyTurin, ItalyGlasgow, UKGenoa, ItalyMilan, ItalyTurin, ItalyFerrara, ItalyPerugia, ItalyTurin, ItalyRome, ItalyHouston, USA Novara, ItalyMilan, ItalyLondon, UKFlorence, ItalyParis, FranceMunich, GermanyLeeds, UKCopenhagen, DenmarkHamburg, GermanyAlessandria, Italy
Alessandra LaroccaMaurizio MartelliMassimo MassaiaGrzegorz S. NowakowskiOwen A. O’Connor Fabrizio PaneStefano A. PileriChristiane PottPatrizia PregnoAlessandro RambaldiLuigi RigacciGiuseppe SaglioValeria SantiniStephen J. SchusterMichele SpinaEnrico TiacciJan Trka Adriano VendittiCarlo ViscoUmberto VitoloElena ZamagniEmanuele Zucca
Turin, ItalyRome, ItalyCuneo, ItalyRochester, USACharlottesville, USA Naples, ItalyMilan, ItalyKiel, GermanyTurin, ItalyBergamo, ItalyRome, ItalyTurin, ItalyFlorence, ItalyPhiladelphia, USAAviano (PN), ItalyPerugia, ItalyPrague, Czech RepublicRome, ItalyVerona, ItalyCandiolo (TO), ItalyBologna, ItalyBellinzona, Switzerland
Unmet challenges in high risk hematological malignancies:
from benchside to clinical practice
MONDAY SEPTEMBER 13, 2021
2 3
09.00 Welcome and introduction M. Ladetto, U. Vitolo and Scientific Authorities
09.30-11.00 Hodgkin Lymphoma and T-cell Lymphoma Chairmen: M. Spina, U. Vitolo
09.30 Genetics and biology of classical Hodgkin Lymphoma: clinical implications E. Tiacci
09.50 How I treat high risk Hodgkin Lymphoma S.M. Ansell
10.10 Histopathology and molecular biology of T-cell Lymphoma S.A. Pileri
10.30 How I treat high risk T-cell Lymphomas O.A. O’Connor
10.50 Panel Discussion
11.00-11.30 LECTURE I Chairman: M. Ladetto
Optimizing outcomes for CD19-directed CAR-T cell therapy in refractory B-cell lymphomas S.J. Schuster
11.30-12.45 Mantle Cell Lymphoma Chairmen: M. Ladetto, M. Martelli 11.30 Biological identification of high risk Mantle Cell Lymphoma C. Pott
11.50 How I treat high risk Mantle Cell Lymphoma in first line O. Hermine
12.10 How I treat relapsed/refractory Mantle Cell Lymphoma C. Visco
12.30 Panel Discussion
12.45-14.00 Lunch
4 5
MONDAY SEPTEMBER 13, 2021 Unmet challenges in high risk hematological malignancies:
from benchside to clinical practice16.00-17.10 Follicular Lymphoma Chairmen: M.Ladetto, L. Rigacci
16.00 Biology of high risk Follicular Lymphoma S. Ferrero
16.20 How I treat high risk Follicular Lymphoma in first line W. Hiddemann
16.40 How I treat relapsed/refractory Follicular Lymphoma N.H. Fowler
17.00 Panel Discussion
17.10-18.20 Chronic Lymphocytic Leukemia Chairmen: A. Cuneo, P. Ghia
17.10 Biology of high risk Chronic Lymphocytic Leukemia M. Massaia
17.30 Defining high risk Chronic Lymphocytic Leukemia in 2021 from the clinician’s perspective J. Gribben
17.50 How I treat relapsed/refractory Chronic Lymphocytic Leukemia P. Hillmen
18.10 Panel Discussion
14.00-14.30 LECTURE II Chairman: U. Vitolo
Impact of Lugano conferences in the lymphoma research E. Zucca
14.30-16.00 Diffuse large B-Cell Lymphoma Chairmen: M. Balzarotti, U. Vitolo 14.30 Biological identification of high risk DLBCL G. Gaidano
14.50 How I treat high risk DLBCL in first line A. Chiappella
15.10 How I treat DLBCL in relapse G.S. Nowakowski
15.30 Novel antibodies in aggressive lymphomas M. Hutchings
15.50 Panel Discussion
6
9.15-10.25 Multiple Myeloma Chairmen: M. Boccadoro, M. Massaia
09.15 Biology of high risk Multiple Myeloma H. Avet-Loiseau
09.35 How I treat young high risk Multiple Myeloma E. Zamagni
09.55 How I treat elderly high risk Multiple Myeloma A. Larocca
10.15 Panel Discussion
10.30-11.00 LECTURE III Chairman: G. Saglio
Beyond 3+7 in Acute Myelogenous Leukemia A.K. Burnett
TUESDAY SEPTEMBER 14, 2021
7
11.00-12.10 Myeloproliferative Disorders Chairmen: A.M. Carella, G. Saglio
11.00 Biology of high risk myeloproliferative disorders P. Guglielmelli
11.20 How I treat high risk Chronic Myeloid Leukemia P. Pregno
11.40 How I treat high risk myeloproliferative neoplasms D. Cilloni
12.00 Panel Discussion
12.10-13.10 Lunch
Unmet challenges in high risk hematological malignancies:
from benchside to clinical practice
TUESDAY SEPTEMBER 14, 2021
13.10-14.20 Acute Lymphoblastic Leukemia and Transplantation Chairmen: R. Foà, A. Rambaldi
13.10 Biology of High Risk Acute Lymphoblastic Leukemia J. Trka
13.30 How I treat high risk Acute Lymphoblastic Leukemia in first line R. Bassan
13.50 Allogeneic transplantation in Acute Myeloid Leukemia and Myelodysplastic Syndromes N. Kroeger
14.10 Panel Discussion
8 9
Unmet challenges in high risk hematological malignancies:
from benchside to clinical practice
14.20-15.30 Acute Myeloblastic Leukemia and Myelodysplastic Syndrome Chairmen: E. Angelucci, F. Pane
14.20 Genomic identification of high risk Acute Myeloid Leukemia B. Falini
14.40 How I treat high risk Myelodysplastic Syndromes V. Santini
15.00 How I treat elderly Acute Myeloid Leukemia patients A. Venditti
15.20 Panel Discussion
15.30-15.45 Closing remarks M. Ladetto, U. Vitolo
stru
chel
.com
MEETING VENUE Starhotels Majestic Corso Vittorio Emanuele II, 5410123 Torino, Italy Tel. +39 011 539153
ITALIAN CME CREDITSAn Italian CME application has been submitted as follows: • Provider Studio ER Congressi SRL: ID 828- 282393. • No. 9,1 CME credits for Physicians (Haematology, Oncology, Internal Medicine) and Biologists.• Educational objective: “linee guida-protocolli-procedure”.
OFFICIAL LANGUAGEEnglish
BADGE AND CERTIFICATE OF ATTENDANCEAll registered participants and speakers will be given a badge which must be worn in order to be admitted to the scientific sessions.A certificate will be given to all participants at the end of the meeting.
SCIENTIFIC BOARD Marco Ladetto MD Associate Professor in HaematologyUniversity of Eastern Piedmont Amedeo AvogadroS.S. Antonio and Biagio and Cesaro Arrigo HospitalVia Venezia, 16 - 15121 Alessandria, Italy
Umberto Vitolo MD Hematology Consultant Candiolo Cancer Institute - FPO-IRCCSStrada Provinciale, 142 - 10060 Candiolo (TO), Italy
SCIENTIFIC COMMITTEEProf. Mario Boccadoro (Turin)Prof. Gianluca Gaidano (Novara)Prof. Massimo Massaia (Cuneo)
Prof. Giuseppe Saglio (Orbassano - TO)
ORGANIZING SECRETARIAT Studio E.R. Congressi Via De’ Poeti, 1/7 - 40124 Bologna, ItalyPhone +39 051 4210559 - Fax +39 051 4210174E-mail: ercongressi@ercongressi.itwww.ercongressi.it
GENERAL INFORMATION
The organization is proud to compensate itsgreenhouse gas emissions investing in thecarbon offset project: “Mytrah Wind Power”.
With an unrestricted educational grant of:
top related